Advanced Biomed ADVB · USD

We are a holding company incorporated in the State of Nevada. In April 2026, we acquired 100% of equity interests of Acellent Technologies (Hong Kong) Co. Limited (“Acellent”), which develops and operates the FinTruth Financial Verification Agent Platform (“FinTruth”), an enterprise AI financial verification platform designed to compare and verify financial analysis and AI-generated financial content against underlying source documents and financial rules, and to produce source-traceable and auditable results. In December 2025 and June 2026, respectively, we sold Advanced Biomed HK (together with its subsidiary, Shanghai Sglcell) and Advanced Biomed Taiwan, thereby disposing of our biomedical operations, and have since fully shifted our focus towards developing our AI application through FinTruth.

Prior to our shift to developing our AI application through FinTruth, we were focused on developing lab devices and chemicals in order to find and study cancer cells in a patient’s blood, with the eventual goal of helping doctors detect and monitor cancer through simple blood tests. Our products included A+Pre, a device that prepares blood samples for testing; the AC-1000, a device that separates cancer cells from the rest of the blood; the A+SCDrop, a device that isolates individual cells; and the A+CellScan, a device that stains and automatically counts cancer cells. We also developed dye kits used to identify different types of cancer cells. With the exception of the A+Pre and AC-1000 devices, most of our products were awaiting regulatory approval from the PRC government.

Quoted from its 10-K, filed 13 Oct 2026. Read the filing on SEC.gov ↗